ACLX
Price
$79.07
Change
+$1.49 (+1.92%)
Updated
Dec 26, 04:59 PM (EDT)
84 days until earnings call
SYRE
Price
$24.07
Change
+$0.73 (+3.13%)
Updated
Dec 26, 04:59 PM (EDT)
63 days until earnings call
Ad is loading...

ACLX vs SYRE

Header iconACLX vs SYRE Comparison
Open Charts ACLX vs SYREBanner chart's image
Arcellx
Price$79.07
Change+$1.49 (+1.92%)
Volume$5.36K
CapitalizationN/A
Spyre Therapeutics
Price$24.07
Change+$0.73 (+3.13%)
Volume$4.99K
CapitalizationN/A
ACLX vs SYRE Comparison Chart
Loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACLX vs. SYRE commentary
Dec 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLX is a StrongBuy and SYRE is a Buy.

Ad is loading...
COMPARISON
Comparison
Dec 27, 2024
Stock price -- (ACLX: $77.58 vs. SYRE: $23.34)
Brand notoriety: ACLX and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACLX: 44% vs. SYRE: 40%
Market capitalization -- ACLX: $4.27B vs. SYRE: $1.44B
ACLX [@Biotechnology] is valued at $4.27B. SYRE’s [@Biotechnology] market capitalization is $1.44B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.39B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACLX’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ACLX’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ACLX is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACLX’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • ACLX’s TA Score: 4 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both ACLX and SYRE are a bad buy in the short-term.

Price Growth

ACLX (@Biotechnology) experienced а -5.42% price change this week, while SYRE (@Biotechnology) price change was -7.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.71%. For the same industry, the average monthly price growth was +0.43%, and the average quarterly price growth was +6.36%.

Reported Earning Dates

ACLX is expected to report earnings on Mar 20, 2025.

SYRE is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (+6.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACLX($4.27B) has a higher market cap than SYRE($1.44B). ACLX YTD gains are higher at: 39.784 vs. SYRE (8.457). ACLX has higher annual earnings (EBITDA): -33.12M vs. SYRE (-195.07M). ACLX has more cash in the bank: 574M vs. SYRE (414M). SYRE has less debt than ACLX: SYRE (0) vs ACLX (65.3M). ACLX has higher revenues than SYRE: ACLX (156M) vs SYRE (0).
ACLXSYREACLX / SYRE
Capitalization4.27B1.44B297%
EBITDA-33.12M-195.07M17%
Gain YTD39.7848.457470%
P/E RatioN/A1.72-
Revenue156M0-
Total Cash574M414M139%
Total Debt65.3M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
85
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACLXSYRE
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 10 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
75%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
77%
Aroon
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Ad is loading...
ACLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FLQL60.180.68
+1.14%
Franklin US Large Cap Mltfctr Idx ETF
IEDI54.620.52
+0.96%
iShares U.S. Consumer Focused ETF
DEW53.040.25
+0.48%
WisdomTree Global High Dividend ETF
EMQQ36.040.07
+0.19%
EMQQ The Emerging Markets Internet ETF
CADJPY109.39N/A
N/A
Canadian Dollar - Japan Yen

ACLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACLX has been loosely correlated with DNLI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ACLX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACLX
1D Price
Change %
ACLX100%
+1.03%
DNLI - ACLX
48%
Loosely correlated
+0.67%
BEAM - ACLX
48%
Loosely correlated
+0.38%
RCKT - ACLX
47%
Loosely correlated
+2.19%
RCUS - ACLX
47%
Loosely correlated
-0.31%
CRSP - ACLX
47%
Loosely correlated
+1.14%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with SNPX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-1.06%
SNPX - SYRE
47%
Loosely correlated
+3.23%
PMN - SYRE
44%
Loosely correlated
-1.63%
APGE - SYRE
44%
Loosely correlated
-0.38%
ABSI - SYRE
43%
Loosely correlated
+2.73%
ACLX - SYRE
41%
Loosely correlated
+1.03%
More